Global Lurasidone Market

Lurasidone Comprehensive Study by Type (20mg/tablet, 40mg/tablet, 60mg/tablet, 80mg/tablet, 120mg/tablet), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End-user (Hospitals, Psychological Clinic, Others) Players and Region - Global Market Outlook to 2030

Lurasidone Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Lurasidone
Lurasidone is a novel antipsychotic agent used to treat certain mental/mood disorders (such as schizophrenia, depression associated with bipolar disorder). It helps to think more clearly, feel less nervous and take part in everyday life. It also helps to improve sleep, appetite, mood and energy level. Lurasidone works by helping to restore the balance of certain natural substances in the brain.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Lurasidone market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sunovion Pharmaceuticals Inc. (United States), Angelini Holding S.p.A. (Italy), Sumitomo Dainippon Pharma Co., Ltd. (Japan), Sigma-Aldrich (United States), Lupin Limited (India), Bushu Pharmaceutical, LTD. (Japan), Zhejiang Hisun Pharmaceutical Co., Ltd. (China), LGM Pharma (United States) and Healthcare Pharmaceuticals Limited (Bangladesh) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Square Pharmaceuticals Ltd. (Bangladesh), Incepta Pharmaceuticals Ltd. (Bangladesh), Maps Laboratories PVT. LTD. (India) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Lurasidone market by Type (20mg/tablet, 40mg/tablet, 60mg/tablet, 80mg/tablet and 120mg/tablet) and Region.



On the basis of geography, the market of Lurasidone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Lurasidone market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-user, the sub-segment i.e. Hospitals will boost the Lurasidone market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in the field of Medical Science

Market Growth Drivers:
Increased Prevalence of Mental/Mood Disorders among People due to Hectic Lifestyle and Rising Regulatory Approvals for Lurasidone

Challenges:
Stringent Government Rules and Regulations

Restraints:
Side Effects such as Serious Drop in Blood Pressure

Opportunities:
Growth in the Healthcare Industry and Robust Increase in Distribution Channels

Market Leaders and their expansionary development strategies
In February 2023, Lupin announced the launch of Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg, to market a generic equivalent of Latuda Tablets of Sunovion Pharmaceuticals, Inc.
In September 2019, Sumitomo Dainippon Pharma Co., Ltd. has announced that Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., its wholly-owned subsidiary in China, launched an atypical antipsychotic LATUDA (generic name: lurasidone hydrochloride) in China for the treatment of adult patients with schizophrenia.


Key Target Audience
Lurasidone Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • 20mg/tablet
  • 40mg/tablet
  • 60mg/tablet
  • 80mg/tablet
  • 120mg/tablet
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End-user
  • Hospitals
  • Psychological Clinic
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Mental/Mood Disorders among People due to Hectic Lifestyle
      • 3.2.2. Rising Regulatory Approvals for Lurasidone
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the field of Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lurasidone, by Type, Distribution Channel, End-user and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lurasidone (Value)
      • 5.2.1. Global Lurasidone by: Type (Value)
        • 5.2.1.1. 20mg/tablet
        • 5.2.1.2. 40mg/tablet
        • 5.2.1.3. 60mg/tablet
        • 5.2.1.4. 80mg/tablet
        • 5.2.1.5. 120mg/tablet
      • 5.2.2. Global Lurasidone by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Lurasidone by: End-user (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Psychological Clinic
        • 5.2.3.3. Others
      • 5.2.4. Global Lurasidone Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Lurasidone (Volume)
      • 5.3.1. Global Lurasidone by: Type (Volume)
        • 5.3.1.1. 20mg/tablet
        • 5.3.1.2. 40mg/tablet
        • 5.3.1.3. 60mg/tablet
        • 5.3.1.4. 80mg/tablet
        • 5.3.1.5. 120mg/tablet
      • 5.3.2. Global Lurasidone by: Distribution Channel (Volume)
        • 5.3.2.1. Hospital Pharmacies
        • 5.3.2.2. Retail Pharmacies
        • 5.3.2.3. Online Pharmacies
      • 5.3.3. Global Lurasidone by: End-user (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Psychological Clinic
        • 5.3.3.3. Others
      • 5.3.4. Global Lurasidone Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Lurasidone (Price)
      • 5.4.1. Global Lurasidone by: Type (Price)
  • 6. Lurasidone: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sunovion Pharmaceuticals Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Angelini Holding S.p.A. (Italy)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sumitomo Dainippon Pharma Co., Ltd. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sigma-Aldrich (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lupin Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bushu Pharmaceutical, LTD. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Zhejiang Hisun Pharmaceutical Co., Ltd. (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LGM Pharma (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Healthcare Pharmaceuticals Limited (Bangladesh)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Lurasidone Sale, by Type, Distribution Channel, End-user and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lurasidone (Value)
      • 7.2.1. Global Lurasidone by: Type (Value)
        • 7.2.1.1. 20mg/tablet
        • 7.2.1.2. 40mg/tablet
        • 7.2.1.3. 60mg/tablet
        • 7.2.1.4. 80mg/tablet
        • 7.2.1.5. 120mg/tablet
      • 7.2.2. Global Lurasidone by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Lurasidone by: End-user (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Psychological Clinic
        • 7.2.3.3. Others
      • 7.2.4. Global Lurasidone Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Lurasidone (Volume)
      • 7.3.1. Global Lurasidone by: Type (Volume)
        • 7.3.1.1. 20mg/tablet
        • 7.3.1.2. 40mg/tablet
        • 7.3.1.3. 60mg/tablet
        • 7.3.1.4. 80mg/tablet
        • 7.3.1.5. 120mg/tablet
      • 7.3.2. Global Lurasidone by: Distribution Channel (Volume)
        • 7.3.2.1. Hospital Pharmacies
        • 7.3.2.2. Retail Pharmacies
        • 7.3.2.3. Online Pharmacies
      • 7.3.3. Global Lurasidone by: End-user (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Psychological Clinic
        • 7.3.3.3. Others
      • 7.3.4. Global Lurasidone Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Lurasidone (Price)
      • 7.4.1. Global Lurasidone by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lurasidone: by Type(USD Million)
  • Table 2. Lurasidone 20mg/tablet , by Region USD Million (2018-2023)
  • Table 3. Lurasidone 40mg/tablet , by Region USD Million (2018-2023)
  • Table 4. Lurasidone 60mg/tablet , by Region USD Million (2018-2023)
  • Table 5. Lurasidone 80mg/tablet , by Region USD Million (2018-2023)
  • Table 6. Lurasidone 120mg/tablet , by Region USD Million (2018-2023)
  • Table 7. Lurasidone: by Distribution Channel(USD Million)
  • Table 8. Lurasidone Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 9. Lurasidone Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 10. Lurasidone Online Pharmacies , by Region USD Million (2018-2023)
  • Table 11. Lurasidone: by End-user(USD Million)
  • Table 12. Lurasidone Hospitals , by Region USD Million (2018-2023)
  • Table 13. Lurasidone Psychological Clinic , by Region USD Million (2018-2023)
  • Table 14. Lurasidone Others , by Region USD Million (2018-2023)
  • Table 15. South America Lurasidone, by Country USD Million (2018-2023)
  • Table 16. South America Lurasidone, by Type USD Million (2018-2023)
  • Table 17. South America Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 18. South America Lurasidone, by End-user USD Million (2018-2023)
  • Table 19. Brazil Lurasidone, by Type USD Million (2018-2023)
  • Table 20. Brazil Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 21. Brazil Lurasidone, by End-user USD Million (2018-2023)
  • Table 22. Argentina Lurasidone, by Type USD Million (2018-2023)
  • Table 23. Argentina Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 24. Argentina Lurasidone, by End-user USD Million (2018-2023)
  • Table 25. Rest of South America Lurasidone, by Type USD Million (2018-2023)
  • Table 26. Rest of South America Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 27. Rest of South America Lurasidone, by End-user USD Million (2018-2023)
  • Table 28. Asia Pacific Lurasidone, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Lurasidone, by Type USD Million (2018-2023)
  • Table 30. Asia Pacific Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 31. Asia Pacific Lurasidone, by End-user USD Million (2018-2023)
  • Table 32. China Lurasidone, by Type USD Million (2018-2023)
  • Table 33. China Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 34. China Lurasidone, by End-user USD Million (2018-2023)
  • Table 35. Japan Lurasidone, by Type USD Million (2018-2023)
  • Table 36. Japan Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 37. Japan Lurasidone, by End-user USD Million (2018-2023)
  • Table 38. India Lurasidone, by Type USD Million (2018-2023)
  • Table 39. India Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 40. India Lurasidone, by End-user USD Million (2018-2023)
  • Table 41. South Korea Lurasidone, by Type USD Million (2018-2023)
  • Table 42. South Korea Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 43. South Korea Lurasidone, by End-user USD Million (2018-2023)
  • Table 44. Taiwan Lurasidone, by Type USD Million (2018-2023)
  • Table 45. Taiwan Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 46. Taiwan Lurasidone, by End-user USD Million (2018-2023)
  • Table 47. Australia Lurasidone, by Type USD Million (2018-2023)
  • Table 48. Australia Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 49. Australia Lurasidone, by End-user USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Lurasidone, by Type USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Lurasidone, by End-user USD Million (2018-2023)
  • Table 53. Europe Lurasidone, by Country USD Million (2018-2023)
  • Table 54. Europe Lurasidone, by Type USD Million (2018-2023)
  • Table 55. Europe Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 56. Europe Lurasidone, by End-user USD Million (2018-2023)
  • Table 57. Germany Lurasidone, by Type USD Million (2018-2023)
  • Table 58. Germany Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 59. Germany Lurasidone, by End-user USD Million (2018-2023)
  • Table 60. France Lurasidone, by Type USD Million (2018-2023)
  • Table 61. France Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 62. France Lurasidone, by End-user USD Million (2018-2023)
  • Table 63. Italy Lurasidone, by Type USD Million (2018-2023)
  • Table 64. Italy Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 65. Italy Lurasidone, by End-user USD Million (2018-2023)
  • Table 66. United Kingdom Lurasidone, by Type USD Million (2018-2023)
  • Table 67. United Kingdom Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 68. United Kingdom Lurasidone, by End-user USD Million (2018-2023)
  • Table 69. Netherlands Lurasidone, by Type USD Million (2018-2023)
  • Table 70. Netherlands Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 71. Netherlands Lurasidone, by End-user USD Million (2018-2023)
  • Table 72. Rest of Europe Lurasidone, by Type USD Million (2018-2023)
  • Table 73. Rest of Europe Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 74. Rest of Europe Lurasidone, by End-user USD Million (2018-2023)
  • Table 75. MEA Lurasidone, by Country USD Million (2018-2023)
  • Table 76. MEA Lurasidone, by Type USD Million (2018-2023)
  • Table 77. MEA Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 78. MEA Lurasidone, by End-user USD Million (2018-2023)
  • Table 79. Middle East Lurasidone, by Type USD Million (2018-2023)
  • Table 80. Middle East Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 81. Middle East Lurasidone, by End-user USD Million (2018-2023)
  • Table 82. Africa Lurasidone, by Type USD Million (2018-2023)
  • Table 83. Africa Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 84. Africa Lurasidone, by End-user USD Million (2018-2023)
  • Table 85. North America Lurasidone, by Country USD Million (2018-2023)
  • Table 86. North America Lurasidone, by Type USD Million (2018-2023)
  • Table 87. North America Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 88. North America Lurasidone, by End-user USD Million (2018-2023)
  • Table 89. United States Lurasidone, by Type USD Million (2018-2023)
  • Table 90. United States Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 91. United States Lurasidone, by End-user USD Million (2018-2023)
  • Table 92. Canada Lurasidone, by Type USD Million (2018-2023)
  • Table 93. Canada Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 94. Canada Lurasidone, by End-user USD Million (2018-2023)
  • Table 95. Mexico Lurasidone, by Type USD Million (2018-2023)
  • Table 96. Mexico Lurasidone, by Distribution Channel USD Million (2018-2023)
  • Table 97. Mexico Lurasidone, by End-user USD Million (2018-2023)
  • Table 98. Lurasidone Sales: by Type(K Units)
  • Table 99. Lurasidone Sales 20mg/tablet , by Region K Units (2018-2023)
  • Table 100. Lurasidone Sales 40mg/tablet , by Region K Units (2018-2023)
  • Table 101. Lurasidone Sales 60mg/tablet , by Region K Units (2018-2023)
  • Table 102. Lurasidone Sales 80mg/tablet , by Region K Units (2018-2023)
  • Table 103. Lurasidone Sales 120mg/tablet , by Region K Units (2018-2023)
  • Table 104. Lurasidone Sales: by Distribution Channel(K Units)
  • Table 105. Lurasidone Sales Hospital Pharmacies , by Region K Units (2018-2023)
  • Table 106. Lurasidone Sales Retail Pharmacies , by Region K Units (2018-2023)
  • Table 107. Lurasidone Sales Online Pharmacies , by Region K Units (2018-2023)
  • Table 108. Lurasidone Sales: by End-user(K Units)
  • Table 109. Lurasidone Sales Hospitals , by Region K Units (2018-2023)
  • Table 110. Lurasidone Sales Psychological Clinic , by Region K Units (2018-2023)
  • Table 111. Lurasidone Sales Others , by Region K Units (2018-2023)
  • Table 112. South America Lurasidone Sales, by Country K Units (2018-2023)
  • Table 113. South America Lurasidone Sales, by Type K Units (2018-2023)
  • Table 114. South America Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 115. South America Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 116. Brazil Lurasidone Sales, by Type K Units (2018-2023)
  • Table 117. Brazil Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 118. Brazil Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 119. Argentina Lurasidone Sales, by Type K Units (2018-2023)
  • Table 120. Argentina Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 121. Argentina Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 122. Rest of South America Lurasidone Sales, by Type K Units (2018-2023)
  • Table 123. Rest of South America Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 124. Rest of South America Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 125. Asia Pacific Lurasidone Sales, by Country K Units (2018-2023)
  • Table 126. Asia Pacific Lurasidone Sales, by Type K Units (2018-2023)
  • Table 127. Asia Pacific Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 128. Asia Pacific Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 129. China Lurasidone Sales, by Type K Units (2018-2023)
  • Table 130. China Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 131. China Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 132. Japan Lurasidone Sales, by Type K Units (2018-2023)
  • Table 133. Japan Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 134. Japan Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 135. India Lurasidone Sales, by Type K Units (2018-2023)
  • Table 136. India Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 137. India Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 138. South Korea Lurasidone Sales, by Type K Units (2018-2023)
  • Table 139. South Korea Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 140. South Korea Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 141. Taiwan Lurasidone Sales, by Type K Units (2018-2023)
  • Table 142. Taiwan Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 143. Taiwan Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 144. Australia Lurasidone Sales, by Type K Units (2018-2023)
  • Table 145. Australia Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 146. Australia Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 147. Rest of Asia-Pacific Lurasidone Sales, by Type K Units (2018-2023)
  • Table 148. Rest of Asia-Pacific Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 149. Rest of Asia-Pacific Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 150. Europe Lurasidone Sales, by Country K Units (2018-2023)
  • Table 151. Europe Lurasidone Sales, by Type K Units (2018-2023)
  • Table 152. Europe Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 153. Europe Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 154. Germany Lurasidone Sales, by Type K Units (2018-2023)
  • Table 155. Germany Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 156. Germany Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 157. France Lurasidone Sales, by Type K Units (2018-2023)
  • Table 158. France Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 159. France Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 160. Italy Lurasidone Sales, by Type K Units (2018-2023)
  • Table 161. Italy Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 162. Italy Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 163. United Kingdom Lurasidone Sales, by Type K Units (2018-2023)
  • Table 164. United Kingdom Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 165. United Kingdom Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 166. Netherlands Lurasidone Sales, by Type K Units (2018-2023)
  • Table 167. Netherlands Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 168. Netherlands Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 169. Rest of Europe Lurasidone Sales, by Type K Units (2018-2023)
  • Table 170. Rest of Europe Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 171. Rest of Europe Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 172. MEA Lurasidone Sales, by Country K Units (2018-2023)
  • Table 173. MEA Lurasidone Sales, by Type K Units (2018-2023)
  • Table 174. MEA Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 175. MEA Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 176. Middle East Lurasidone Sales, by Type K Units (2018-2023)
  • Table 177. Middle East Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 178. Middle East Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 179. Africa Lurasidone Sales, by Type K Units (2018-2023)
  • Table 180. Africa Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 181. Africa Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 182. North America Lurasidone Sales, by Country K Units (2018-2023)
  • Table 183. North America Lurasidone Sales, by Type K Units (2018-2023)
  • Table 184. North America Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 185. North America Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 186. United States Lurasidone Sales, by Type K Units (2018-2023)
  • Table 187. United States Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 188. United States Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 189. Canada Lurasidone Sales, by Type K Units (2018-2023)
  • Table 190. Canada Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 191. Canada Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 192. Mexico Lurasidone Sales, by Type K Units (2018-2023)
  • Table 193. Mexico Lurasidone Sales, by Distribution Channel K Units (2018-2023)
  • Table 194. Mexico Lurasidone Sales, by End-user K Units (2018-2023)
  • Table 195. Lurasidone: by Type(USD/Units)
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Lurasidone: by Type(USD Million)
  • Table 206. Lurasidone 20mg/tablet , by Region USD Million (2025-2030)
  • Table 207. Lurasidone 40mg/tablet , by Region USD Million (2025-2030)
  • Table 208. Lurasidone 60mg/tablet , by Region USD Million (2025-2030)
  • Table 209. Lurasidone 80mg/tablet , by Region USD Million (2025-2030)
  • Table 210. Lurasidone 120mg/tablet , by Region USD Million (2025-2030)
  • Table 211. Lurasidone: by Distribution Channel(USD Million)
  • Table 212. Lurasidone Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 213. Lurasidone Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 214. Lurasidone Online Pharmacies , by Region USD Million (2025-2030)
  • Table 215. Lurasidone: by End-user(USD Million)
  • Table 216. Lurasidone Hospitals , by Region USD Million (2025-2030)
  • Table 217. Lurasidone Psychological Clinic , by Region USD Million (2025-2030)
  • Table 218. Lurasidone Others , by Region USD Million (2025-2030)
  • Table 219. South America Lurasidone, by Country USD Million (2025-2030)
  • Table 220. South America Lurasidone, by Type USD Million (2025-2030)
  • Table 221. South America Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 222. South America Lurasidone, by End-user USD Million (2025-2030)
  • Table 223. Brazil Lurasidone, by Type USD Million (2025-2030)
  • Table 224. Brazil Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 225. Brazil Lurasidone, by End-user USD Million (2025-2030)
  • Table 226. Argentina Lurasidone, by Type USD Million (2025-2030)
  • Table 227. Argentina Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 228. Argentina Lurasidone, by End-user USD Million (2025-2030)
  • Table 229. Rest of South America Lurasidone, by Type USD Million (2025-2030)
  • Table 230. Rest of South America Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 231. Rest of South America Lurasidone, by End-user USD Million (2025-2030)
  • Table 232. Asia Pacific Lurasidone, by Country USD Million (2025-2030)
  • Table 233. Asia Pacific Lurasidone, by Type USD Million (2025-2030)
  • Table 234. Asia Pacific Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 235. Asia Pacific Lurasidone, by End-user USD Million (2025-2030)
  • Table 236. China Lurasidone, by Type USD Million (2025-2030)
  • Table 237. China Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 238. China Lurasidone, by End-user USD Million (2025-2030)
  • Table 239. Japan Lurasidone, by Type USD Million (2025-2030)
  • Table 240. Japan Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 241. Japan Lurasidone, by End-user USD Million (2025-2030)
  • Table 242. India Lurasidone, by Type USD Million (2025-2030)
  • Table 243. India Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 244. India Lurasidone, by End-user USD Million (2025-2030)
  • Table 245. South Korea Lurasidone, by Type USD Million (2025-2030)
  • Table 246. South Korea Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 247. South Korea Lurasidone, by End-user USD Million (2025-2030)
  • Table 248. Taiwan Lurasidone, by Type USD Million (2025-2030)
  • Table 249. Taiwan Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 250. Taiwan Lurasidone, by End-user USD Million (2025-2030)
  • Table 251. Australia Lurasidone, by Type USD Million (2025-2030)
  • Table 252. Australia Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 253. Australia Lurasidone, by End-user USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Lurasidone, by Type USD Million (2025-2030)
  • Table 255. Rest of Asia-Pacific Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 256. Rest of Asia-Pacific Lurasidone, by End-user USD Million (2025-2030)
  • Table 257. Europe Lurasidone, by Country USD Million (2025-2030)
  • Table 258. Europe Lurasidone, by Type USD Million (2025-2030)
  • Table 259. Europe Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 260. Europe Lurasidone, by End-user USD Million (2025-2030)
  • Table 261. Germany Lurasidone, by Type USD Million (2025-2030)
  • Table 262. Germany Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 263. Germany Lurasidone, by End-user USD Million (2025-2030)
  • Table 264. France Lurasidone, by Type USD Million (2025-2030)
  • Table 265. France Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 266. France Lurasidone, by End-user USD Million (2025-2030)
  • Table 267. Italy Lurasidone, by Type USD Million (2025-2030)
  • Table 268. Italy Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 269. Italy Lurasidone, by End-user USD Million (2025-2030)
  • Table 270. United Kingdom Lurasidone, by Type USD Million (2025-2030)
  • Table 271. United Kingdom Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 272. United Kingdom Lurasidone, by End-user USD Million (2025-2030)
  • Table 273. Netherlands Lurasidone, by Type USD Million (2025-2030)
  • Table 274. Netherlands Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 275. Netherlands Lurasidone, by End-user USD Million (2025-2030)
  • Table 276. Rest of Europe Lurasidone, by Type USD Million (2025-2030)
  • Table 277. Rest of Europe Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 278. Rest of Europe Lurasidone, by End-user USD Million (2025-2030)
  • Table 279. MEA Lurasidone, by Country USD Million (2025-2030)
  • Table 280. MEA Lurasidone, by Type USD Million (2025-2030)
  • Table 281. MEA Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 282. MEA Lurasidone, by End-user USD Million (2025-2030)
  • Table 283. Middle East Lurasidone, by Type USD Million (2025-2030)
  • Table 284. Middle East Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 285. Middle East Lurasidone, by End-user USD Million (2025-2030)
  • Table 286. Africa Lurasidone, by Type USD Million (2025-2030)
  • Table 287. Africa Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 288. Africa Lurasidone, by End-user USD Million (2025-2030)
  • Table 289. North America Lurasidone, by Country USD Million (2025-2030)
  • Table 290. North America Lurasidone, by Type USD Million (2025-2030)
  • Table 291. North America Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 292. North America Lurasidone, by End-user USD Million (2025-2030)
  • Table 293. United States Lurasidone, by Type USD Million (2025-2030)
  • Table 294. United States Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 295. United States Lurasidone, by End-user USD Million (2025-2030)
  • Table 296. Canada Lurasidone, by Type USD Million (2025-2030)
  • Table 297. Canada Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 298. Canada Lurasidone, by End-user USD Million (2025-2030)
  • Table 299. Mexico Lurasidone, by Type USD Million (2025-2030)
  • Table 300. Mexico Lurasidone, by Distribution Channel USD Million (2025-2030)
  • Table 301. Mexico Lurasidone, by End-user USD Million (2025-2030)
  • Table 302. Lurasidone Sales: by Type(K Units)
  • Table 303. Lurasidone Sales 20mg/tablet , by Region K Units (2025-2030)
  • Table 304. Lurasidone Sales 40mg/tablet , by Region K Units (2025-2030)
  • Table 305. Lurasidone Sales 60mg/tablet , by Region K Units (2025-2030)
  • Table 306. Lurasidone Sales 80mg/tablet , by Region K Units (2025-2030)
  • Table 307. Lurasidone Sales 120mg/tablet , by Region K Units (2025-2030)
  • Table 308. Lurasidone Sales: by Distribution Channel(K Units)
  • Table 309. Lurasidone Sales Hospital Pharmacies , by Region K Units (2025-2030)
  • Table 310. Lurasidone Sales Retail Pharmacies , by Region K Units (2025-2030)
  • Table 311. Lurasidone Sales Online Pharmacies , by Region K Units (2025-2030)
  • Table 312. Lurasidone Sales: by End-user(K Units)
  • Table 313. Lurasidone Sales Hospitals , by Region K Units (2025-2030)
  • Table 314. Lurasidone Sales Psychological Clinic , by Region K Units (2025-2030)
  • Table 315. Lurasidone Sales Others , by Region K Units (2025-2030)
  • Table 316. South America Lurasidone Sales, by Country K Units (2025-2030)
  • Table 317. South America Lurasidone Sales, by Type K Units (2025-2030)
  • Table 318. South America Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 319. South America Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 320. Brazil Lurasidone Sales, by Type K Units (2025-2030)
  • Table 321. Brazil Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 322. Brazil Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 323. Argentina Lurasidone Sales, by Type K Units (2025-2030)
  • Table 324. Argentina Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 325. Argentina Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 326. Rest of South America Lurasidone Sales, by Type K Units (2025-2030)
  • Table 327. Rest of South America Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 328. Rest of South America Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 329. Asia Pacific Lurasidone Sales, by Country K Units (2025-2030)
  • Table 330. Asia Pacific Lurasidone Sales, by Type K Units (2025-2030)
  • Table 331. Asia Pacific Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 332. Asia Pacific Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 333. China Lurasidone Sales, by Type K Units (2025-2030)
  • Table 334. China Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 335. China Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 336. Japan Lurasidone Sales, by Type K Units (2025-2030)
  • Table 337. Japan Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 338. Japan Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 339. India Lurasidone Sales, by Type K Units (2025-2030)
  • Table 340. India Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 341. India Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 342. South Korea Lurasidone Sales, by Type K Units (2025-2030)
  • Table 343. South Korea Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 344. South Korea Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 345. Taiwan Lurasidone Sales, by Type K Units (2025-2030)
  • Table 346. Taiwan Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 347. Taiwan Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 348. Australia Lurasidone Sales, by Type K Units (2025-2030)
  • Table 349. Australia Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 350. Australia Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 351. Rest of Asia-Pacific Lurasidone Sales, by Type K Units (2025-2030)
  • Table 352. Rest of Asia-Pacific Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 353. Rest of Asia-Pacific Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 354. Europe Lurasidone Sales, by Country K Units (2025-2030)
  • Table 355. Europe Lurasidone Sales, by Type K Units (2025-2030)
  • Table 356. Europe Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 357. Europe Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 358. Germany Lurasidone Sales, by Type K Units (2025-2030)
  • Table 359. Germany Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 360. Germany Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 361. France Lurasidone Sales, by Type K Units (2025-2030)
  • Table 362. France Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 363. France Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 364. Italy Lurasidone Sales, by Type K Units (2025-2030)
  • Table 365. Italy Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 366. Italy Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 367. United Kingdom Lurasidone Sales, by Type K Units (2025-2030)
  • Table 368. United Kingdom Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 369. United Kingdom Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 370. Netherlands Lurasidone Sales, by Type K Units (2025-2030)
  • Table 371. Netherlands Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 372. Netherlands Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 373. Rest of Europe Lurasidone Sales, by Type K Units (2025-2030)
  • Table 374. Rest of Europe Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 375. Rest of Europe Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 376. MEA Lurasidone Sales, by Country K Units (2025-2030)
  • Table 377. MEA Lurasidone Sales, by Type K Units (2025-2030)
  • Table 378. MEA Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 379. MEA Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 380. Middle East Lurasidone Sales, by Type K Units (2025-2030)
  • Table 381. Middle East Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 382. Middle East Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 383. Africa Lurasidone Sales, by Type K Units (2025-2030)
  • Table 384. Africa Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 385. Africa Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 386. North America Lurasidone Sales, by Country K Units (2025-2030)
  • Table 387. North America Lurasidone Sales, by Type K Units (2025-2030)
  • Table 388. North America Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 389. North America Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 390. United States Lurasidone Sales, by Type K Units (2025-2030)
  • Table 391. United States Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 392. United States Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 393. Canada Lurasidone Sales, by Type K Units (2025-2030)
  • Table 394. Canada Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 395. Canada Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 396. Mexico Lurasidone Sales, by Type K Units (2025-2030)
  • Table 397. Mexico Lurasidone Sales, by Distribution Channel K Units (2025-2030)
  • Table 398. Mexico Lurasidone Sales, by End-user K Units (2025-2030)
  • Table 399. Lurasidone: by Type(USD/Units)
  • Table 400. Research Programs/Design for This Report
  • Table 401. Key Data Information from Secondary Sources
  • Table 402. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lurasidone: by Type USD Million (2018-2023)
  • Figure 5. Global Lurasidone: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Lurasidone: by End-user USD Million (2018-2023)
  • Figure 7. South America Lurasidone Share (%), by Country
  • Figure 8. Asia Pacific Lurasidone Share (%), by Country
  • Figure 9. Europe Lurasidone Share (%), by Country
  • Figure 10. MEA Lurasidone Share (%), by Country
  • Figure 11. North America Lurasidone Share (%), by Country
  • Figure 12. Global Lurasidone: by Type K Units (2018-2023)
  • Figure 13. Global Lurasidone: by Distribution Channel K Units (2018-2023)
  • Figure 14. Global Lurasidone: by End-user K Units (2018-2023)
  • Figure 15. South America Lurasidone Share (%), by Country
  • Figure 16. Asia Pacific Lurasidone Share (%), by Country
  • Figure 17. Europe Lurasidone Share (%), by Country
  • Figure 18. MEA Lurasidone Share (%), by Country
  • Figure 19. North America Lurasidone Share (%), by Country
  • Figure 20. Global Lurasidone: by Type USD/Units (2018-2023)
  • Figure 21. Global Lurasidone share by Players 2023 (%)
  • Figure 22. Global Lurasidone share by Players (Top 3) 2023(%)
  • Figure 23. Global Lurasidone share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Sunovion Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Sunovion Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Angelini Holding S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 28. Angelini Holding S.p.A. (Italy) Revenue: by Geography 2023
  • Figure 29. Sumitomo Dainippon Pharma Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Sumitomo Dainippon Pharma Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 31. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 32. Sigma-Aldrich (United States) Revenue: by Geography 2023
  • Figure 33. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Lupin Limited (India) Revenue: by Geography 2023
  • Figure 35. Bushu Pharmaceutical, LTD. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Bushu Pharmaceutical, LTD. (Japan) Revenue: by Geography 2023
  • Figure 37. Zhejiang Hisun Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 38. Zhejiang Hisun Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 39. LGM Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 40. LGM Pharma (United States) Revenue: by Geography 2023
  • Figure 41. Healthcare Pharmaceuticals Limited (Bangladesh) Revenue, Net Income and Gross profit
  • Figure 42. Healthcare Pharmaceuticals Limited (Bangladesh) Revenue: by Geography 2023
  • Figure 43. Global Lurasidone: by Type USD Million (2025-2030)
  • Figure 44. Global Lurasidone: by Distribution Channel USD Million (2025-2030)
  • Figure 45. Global Lurasidone: by End-user USD Million (2025-2030)
  • Figure 46. South America Lurasidone Share (%), by Country
  • Figure 47. Asia Pacific Lurasidone Share (%), by Country
  • Figure 48. Europe Lurasidone Share (%), by Country
  • Figure 49. MEA Lurasidone Share (%), by Country
  • Figure 50. North America Lurasidone Share (%), by Country
  • Figure 51. Global Lurasidone: by Type K Units (2025-2030)
  • Figure 52. Global Lurasidone: by Distribution Channel K Units (2025-2030)
  • Figure 53. Global Lurasidone: by End-user K Units (2025-2030)
  • Figure 54. South America Lurasidone Share (%), by Country
  • Figure 55. Asia Pacific Lurasidone Share (%), by Country
  • Figure 56. Europe Lurasidone Share (%), by Country
  • Figure 57. MEA Lurasidone Share (%), by Country
  • Figure 58. North America Lurasidone Share (%), by Country
  • Figure 59. Global Lurasidone: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Sunovion Pharmaceuticals Inc. (United States)
  • Angelini Holding S.p.A. (Italy)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Sigma-Aldrich (United States)
  • Lupin Limited (India)
  • Bushu Pharmaceutical, LTD. (Japan)
  • Zhejiang Hisun Pharmaceutical Co., Ltd. (China)
  • LGM Pharma (United States)
  • Healthcare Pharmaceuticals Limited (Bangladesh)
Additional players considered in the study are as follows:
Square Pharmaceuticals Ltd. (Bangladesh) , Incepta Pharmaceuticals Ltd. (Bangladesh) , Maps Laboratories PVT. LTD. (India) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 232 Pages 53 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lurasidone Market Quantitative research analysis
Global Lurasidone Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sunovion Pharmaceuticals Inc. (United States), Angelini Holding S.p.A. (Italy), Sumitomo Dainippon Pharma Co., Ltd. (Japan), Sigma-Aldrich (United States), Lupin Limited (India), Bushu Pharmaceutical, LTD. (Japan), Zhejiang Hisun Pharmaceutical Co., Ltd. (China), LGM Pharma (United States) and Healthcare Pharmaceuticals Limited (Bangladesh) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in the field of Medical Science" is seen as one of major influencing trends for Lurasidone Market during projected period 2023-2030.
The Lurasidone market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Lurasidone Market Report?

Have a Query? Click Here

Other Related Reports

Peptide Based Cardiovascular Therapeutics Comprehensive Study by Type (Generic, Innovative), Route of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal, Others), Synthesis Technology (...
$ 3450
Streptococcus Pneumoniae Vaccine Comprehensive Study by Type (Pneumococcal Conjugate Vaccine (PCV), Pneumococcal Polysaccharide Vaccine (PPV)), Application (Clinics, Hospitals), Vaccine Type (Synflor...
$ 3650
Achondroplasty Treatment Drug Comprehensive Study by Type (Lipase Inhibitor, Appetite Suppresants, Human Growth Hormone), Application (Hospital, Clinic, Others), Patient Type (Adult, Paediatric), Dis...
$ 3450
Betahistine Comprehensive Study by Type (8mg, 16mg, 24mg), Application (Vertigo, Tinnitus, Nausea), Sales Channel (Online, Offline) Players and Region - Global Market Outlook to 2026
$ 3500
Pilocarpine Comprehensive Study by Type (Pilocarpine Tablets, Pilocarpine Eye Drops), Application (Dry Mouth, Gluacom or Ocular Hypertension), Distribution Channel (Hospital Pharmacies, Retail Pharma...
$ 3450
Decitabine Drug Comprehensive Study by Type (Prescription, Over-the-Counter), Application (Myelodysplastic syndrome, Acute Myeloid Leukemia), Distribution Channel (Hospital Pharmacies, Drug Store, Re...
$ 3450